Prostate-specific antigen levels in hypertensive patients suffering from a non-ST elevation myocardial infarction or a new-onset atrial fibrillation

International Journal of Cardiology

Volumn 158, Issue 3, 2012, Pages 380-382

  Patanè, Salvatore ^a   Marte, Filippo ^a  

^a Cardiologia Ospedale San Vincenzo   (Italy)

Author keywords

Age specific PSA ranges (a.s. PSA); New onset atrial fibrillation(AFIB); Non ST elevation myocardial infarction (NSTEMI); Prostate specific antigen kallikrein (PSA)

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING;

ADULT; AGE DISTRIBUTION; AGED; ATRIAL FIBRILLATION; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; ELECTROCARDIOGRAPHY; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 84863629924     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.01.066     Document Type: Article

References (43)

1. Patanè S, Marte F. Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system. Eur Heart J. 2009 May;30(10):1169-70. Electronic publication ahead of print 2009 Apr 10.
2. J. Koller-Strametz, M. Fritzer, and M. Gwechenberger Elevation of prostate-specific markers after cardiopulmonary resuscitation Circulation 102 3 Jul 18 2000 290 293
3. R. Berent, J. Auer, and M. Porodko Influence of cardiopulmonary resuscitation on levels of tumour markers Eur J Cancer Care (Engl) 15 3 Jul 2006 252 256
4. R.A. Mahfouz, N.K. Cortas, G. Ibrahim, S. Khalife, and R.T. Daher Variations in prostate-specific antigen free/total ratio in acute stress Scand J Clin Lab Invest 68 7 2008 624 627
5. P.G. Hagood, R.O. Parra, and J.A. Rauscher Nontraumatic evaluation of prostate specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass J Urol 152 1994 2043 2045
6. B.S. Parlaktas, E. Naseri, N. Uluocak, A.O. Elalmis, F. Erdemir, and I. Etikan Comparison of the effects of on-pump versus off-pump coronary artery bypass surgery on serum prostate-specific antigen levels Int J Urol 13 3 Mar 2006 234 237
7. N.R. Netto Júnior, M.L. Lima, M.A. Guedes, L.L. Patino, and J.B. de Oliveira Elevation of prostate specific antigen in cardiac surgery with extracorporeal cardiopulmonary circulation J Urol 159 3 Mar 1998 875 877
8. S. Guvel, R. Turkoz, and T. Egilmez Does ischemia-induced prostate damage during cardiac surgery involving cardiopulmonary bypass cause bladder outlet obstruction? Urol Int 74 4 2005 337 340
9. M. Koreny, J. Koller-Strametz, and A. Geppert Elevation of prostatic markers following cardiogenic shock Intensive Care Med 27 2 Feb 2001 447
10. M. Crook, K. Preston, and I. Lancaster Serum prostatic specific-antigen concentrations in acute myocardial infarction Clin Chem 43 9 Sep 1997 1670
11. Patanè S, Marte F, Paroxysmal Ventricular Tachycardia And Paroxysmal Atrial Fibrillation Associated With Subclinical Hyperthyroidism, Chronic Renal Failure And Elevation Of Prostate Specific Antigen During Acute Myocardial Infarction. Int J Cardiol. 2008 Aug 21; Electronic publication ahead of print.
12. Patanè S, Marte F, Di Bella G, Ciccarello G. Changing axis deviation and elevation of prostate-specific antigen during acute myocardial infarction.Int J Cardiol. 2009 Jun 12;135(1):e4-5. Electronic publication ahead of print 2008 Jun 25.
13. Patanè S, Marte F, Di Bella G, Ciccarello G. Changing axis deviation, paroxysmal atrial fibrillation and elevation of prostate-specific antigen during acute myocardial infarction. Int J Cardiol. 2009 Oct 2;137(2):e37-40. Electronic publication ahead of print 2008 Aug 8.
14. Patanè S, Marte F, Sturiale M, Grassi R, Patanè F. Significant coronary artery disease associated with coronary artery aneurysm and elevation of prostate-specific antigen during acute myocardial infarction. Int J Cardiol. 2010 Jun 11;141(3):e39-42. Electronic publication ahead of print 2009 Jan 12.
15. Patanè S, Marte F, Sturiale M. Prostate-specific antigen kallikrein complexes and acute myocardial infarction. Int J Cardiol. 2009 July 17; Electronic publication ahead of print.
16. S. Patanè Prostate-specific antigen kallikrein and the heart World J Cardiol 1 1 December 31 2009 23 25
17. T. Ozcan, M. Bozlu, N. Muslu, K. Gozukara, S. Seyis, and B. Akcay Elevation of the serum total and free prostate specific antigen levels after stent implantation in patients with coronary artery disease Swiss Med Wkly 139 45-46 2009 672 675
18. Patanè S, Marte F, Prostate-specific antigen kallikrein and acute myocardial infarction:where we are. Where are we going ? Int J Cardiol. 2008 Jan 30; Electronic publication ahead of print.
19. Patanè S, Marte F, Prostate-specific antigen and acute myocardial infarction: a possible new intriguing scenario. Int J Cardiol. 2009 May 29;134(3):e147-9. Electronic publication ahead of print 2009 Jan 21.
20. Patanè S, Marte F, Sturiale M, Dattilo G. ST-segment elevation and diminution of prostate specific antigen in a patient with coronary spasm and without significant coronary stenoses.Int J Cardiol. 2009 Mar 23. [Electronic publication ahead of print].
21. Vyssoulis G, Karpanou E, Kyvelou SM, Vlachopoulos C, Tzamou V, Stefanadis C. Prostate-Specific Antigen Levels Are Associated with Arterial Stiffness in Essential Hypertensive Patients. J Sex Med. 2010 Aug 16. [Electronic publication ahead of print].
22. G.F. Mitchell, Y. Lacourciere, and J.P. Ouellet Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationship Circulation 108 2003 1592 1598
23. G.F. Mitchell, L.A. Moye, and E. Braunwald Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function, SAVE investigators: survival and ventricular enlargement Circulation 96 1997 4254 4260
24. G.F. Mitchell, R.S. Vasan, and M.J. Keyes Pulse pressure and risk of new-onset atrial fibrillation JAMA 297 2007 709 715
25. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine.ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007 Aug 14;50(7):e1-e157. No abstract available. Erratum in: J Am Coll Cardiol. 2008 Mar 4;51(9):974. Circulation. 2007 Aug 14;116(7):e148-304. Epub 2007 Aug 6. No abstract available. Erratum in: Circulation. 2008 Mar 4;117(9):e180.
26. J.E. Oesterling, S.J. Jacobsen, and C.G. Chute Serum prostate specific antigen in a community based population of healthy men: establishment of age-specific reference ranges JAMA 270 7 Aug 18 1993 860 864
27. G.J. Gormley, E. Stoner, R.C. Bruskewitz for the Finasteride Study Group The effect of finasteride in men with benign prostatic hyperplasia N Engl J Med 327 17 1992 Oct 22 1185 1191
28. Juang HH, Lin YF, Chang PL, Tsui KH. Cardiac glycosides decrease prostate specific antigen expression by down-regulation of prostate derived ets factor.J Urol. 2010 Nov;184(5):2158-64. Epub 2010 Sep 17.
29. Chang SL, Harshman LC, Presti JC Jr. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol. 2010 Sep 1;28(25):3951-7. Epub 2010 Aug 2.
30. A.S. Murad, L. Down, and G. Davey Smith Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study) Int J Cancer 128 6 2011 Mar 15 1442 1448
31. A.M. Algotar, P.A. Thompson, and J. Ranger-Moore Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity Prostate 70 8 Jun 1 2010 883 888
32. Fowke JH, Motley SS, Smith JA Jr, Cookson MS, Concepcion R, Chang SS, Byerly S. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume.J Urol. 2009 May;181(5):2064-70. Epub 2009 Mar 14.
33. D.J. Mener Prostate specific antigen reduction following statin therapy: mechanism of action and review of the literature IUBMB Life 62 8 Aug 2010 584 590
34. D.M. Lloyd-Jones, T.J. Wang, and E.P. Leip Lifetime risk for development of atrial fibrillation: The Framingham Heart Study Circulation 110 2004 1042 1046
35. E.J. Benjamin, D. Levy, S.M. Vaziri, R.B. D'Agostino, A.J. Belanger, and P.A. Wolf Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study JAMA 271 1994 840 844
36. A.F. Nash, and I. Melezinek The role of prostate specific antigen measurement in the detection and management of prostate cancer Endocr Relat Cancer 7 1 Mar 2000 37 51 Review
37. H.G. Rittenhouse, J.A. Finlay, S.D. Mikolajczyk, and A.W. Partin Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate Crit Rev Clin Lab Sci 35 1998 275 368
38. L. Jia, and G.A. Coetzee Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus Cancer Res 65 17 Sep 1 2005 8003 8008
39. H.C. Wu, J.T. Hsieh, M.E. Gleave, N.M. Brown, S. Pathak, and L.W. Chung Derivation of androgen independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells Int J Cancer 57 3 May 1 1994 406 412
40. S. Kamoshida, and Y. Tsutsumi Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland Hum Pathol 21 11 Nov 1990 1108 1111
41. P. Henttu, and P. Vihko Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line J Steroid Biochem Mol Biol 41 3-8 1992 Mar 349 360
42. D.A. Wolf, P. Schulz, and F. Fittler Transcriptional regulation of prostate kallikrein-like genes by androgen Mol Endocrinol 6 5 May 1992 753 762
43. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2